methotrexate 50mg/ml solution for injection (Metoject®)

following an abbreviated submission:

methotrexate 50mg/mL solution for injection (Metoject®) is accepted for use within NHS Scotland.

Indication under review: polyarthritic forms of severe active juvenile idiopathic arthritis, when the response to non-steroidal anti-inflammatory drugs has been inadequate.

For patients in whom treatment with disease modifying drugs is indicated and parenteral administration of methotrexate is appropriate, this adds to the range of pre filled syringes available.

The Scottish Medicines Consortium has previously accepted methotrexate for the treatment of severe active rheumatoid arthritis in adult patients where treatment with disease modifying drugs is indicated. Methotrexate injection is listed in the British National Formulary for Children 2010 -11 for the treatment of juvenile idiopathic arthritis.